Windhover Information and IMS Health proudly present the first webinar in their
 Pharma Strategies Webinar Series:

Managing Current Challenges
to Ensure Future Growth

The Pharma Strategies
Webinar Series

Click here to register!

Managing Current Challenges to Ensure Future Growth
June 12

Hear industry professionals discuss how to address the challenges every executive is facing – from reigning in the high costs of R&D and marketing to declining research productivity, pricing pressures and regulatory constraints.

A New Look at
Primary Care
July 17

In 2008, the primary care-driven segment of the global pharmaceutical market will go negative for the first time. Join industry experts as they explore how pharmaceutical companies can instill a “whole product” approach to their medications.

Adapting the Business Model to Ensure Success Oct. 9

Hear industry experts discuss the winning business models of tomorrow as they draw on best-practice examples from highly successful non-pharmaceutical models – and how these strategies can be applied to pharma and biotech firms.

 

For more information on Windhover products and conferences, visit us at www.windhover.com,
or send an email to conferences@windhover.com.
10 Hoyt St., Norwalk, CT 06851
* Tel: +1 (203) 838-4401 x 113
* Fax: +1 (203) 838-3214

A FREE webinar
Thursday, June 12, 2008 • 12 PM ET / 9 AM PT • 90 minutes

About the event • Key Topics • Who Should Attend • Benefits • Speakers • Register • About the Series

Featuring

Roger Longman (moderator)
Managing Partner / Windhover Information
Publisher / IN VIVO, Start-Up and The RPM Report

Jerry Cacciotti
Vice President / SDG Life Sciences, a Unit of IMS

Richard Evans
Vice President / AVOS Life Sciences

Mary Tanner
Founder / Life Sciences Partners

Negative growth trends in both the U.S. and global markets are fueling widespread speculation about long-term prospects for the pharmaceutical market. New market forces, including a shift to specialty products, increased payer influence and uncertain regulatory approvals are causing industry leaders to re-think their current strategies as they address these growth challenges.

In this webinar, Roger Longman leads a panel of experts to provide a new strategic framework for today’s decision makers:

  • How to address rising R&D and marketing costs
  • What to do about increasing pricing pressures and regulatory constraints
  • Which business development strategies make sense given pipeline prospects
  • Where to play — and how to win — in increasingly crowded markets

REGISTER NOW!

This is a must-attend session for leaders in business development, portfolio strategy, brand management and strategic planning, as well as other commercial areas within pharma and biotech companies. Whether you’re launching a new brand, evaluating your pipeline prospects or are questioning your current commercial strategy, you’ll get fresh insights and immediately-applicable strategies.

So join us, in the convenience of your own office, for a thought-provoking analysis of the issues central to your company's success. Grab your team (or several teams), a conference room at your office, a phone and a computer with Web access (that last one's optional). No travel required.

Back to top

Key discussion highlights include:

  • Business models for success
  • Getting control of the high costs of R&D and marketing
  • Overcoming declining research productivity, pricing pressures and regulatory constraints
  • Opportunities for future growth

Back to top

Pharma and biotech senior executives in:

  • business development
  • portfolio strategy
  • brand management
  • strategic planning,
  • other commercial areas

Back to top

 

 

Roger Longman
Managing Partner
Windhover Information

Roger Longman is a Managing Partner at Windhover Information Inc. and has been involved with the health care industry for more than 20 years. Over the years, he has become recognized as one of the leading experts in pharm/bio dealmaking.

Mr. Longman is regularly asked to speak at many key industry events as well as at leading pharma and biotech companies. He lectures regularly at leading universities and co-directs, with The Wharton School, an annual week-long course on the pharmaceutical industry.

In 1983, Mr. Longman joined The Wilkerson Group as a writer covering the pharmaceutical and biotech industries for IN VIVO: The Business & Medicine Report.™ As editor of IN VIVO, he recognized the demand for health care transaction research and created a database to track health care transactions, the industry-leading Strategic Transactions Database.

In 1989, Mr. Longman, along with partner David Cassak, led a buyout of the publications business of The Wilkerson Group, forming Windhover Information Inc. Mr. Longman and Mr. Cassak, recognizing the demand for health care business investment information, launched various other monthly health care industry journals. In addition to IN VIVO, widely recognized as the premier provider of business intelligence in the health care industry, Windhover’s publications include Start-Up: Emerging Medical Ventures,™ and The RPM Report: Regulation / Policy / Market Access.™ In 2005, Windhover also acquired Medtech Insight Inc., and now publishes Medtech Insight: Medical Technology Market Intelligence.®

Mr. Longman was also critical in the creation of Windhover's conference division, which produces numerous influential conferences every year and is well-known for, among others, its Pharmaceutical Strategic Alliances, Euro-Biotech Forum and BIO-Windhover meetings. Since the acquisition of Medtech Insight, Windhover also hosts that company’s respected Investment in Innovation (In3) partnering conferences around the world.

Mr. Longman completed his BA at Cornell University and an MA at the University of North Carolina at Chapel Hill, and then taught for three years at the European division of the University of Maryland.

 

 

Jerry Cacciotti
Vice President
SDG Life Sciences, a Unit of IMS

Jerry Cacciotti leads the SDG Life Sciences unit of IMS. Specializing in corporate portfolio strategy, Mr. Cacciotti has lead clients through major strategy transitions — from decisions to entering new regions or business sectors, to exiting or investing in multi-billion-dollar franchises, to realigning business strategies at the broadest level. He has supported clients through the M&A process, supporting transactions worth hundreds of billions of dollars, and has extensive experience in valuation and negotiation strategy.

Mr. Cacciotti has led significant engagements involving most therapeutic categories particularly in oncology, respiratory, and cardiovascular therapy, working with clients in Europe, North America and Japan. His recent work has focused on frameworks to integrate strategic choices with shareholder and financial market expectations. He recently co-authored an article on changes in the traditional pharmaceutical business model, Pharma’s Next Model, which appeared in Pharmaceutical Executive magazine.

 

 

Richard Evans
Vice President
AVOS Life Sciences

Richard Evans served as a Senior Analyst covering the US pharmaceuticals industry at Sanford C. Bernstein & Co., LLC, from 1998 until 2006. He was twice ranked first amongst his peers for drug stock selection by Bloomberg, and in 2006 was ranked amongst the top 20 stock pickers on Wall Street by Bloomberg. Dr. Evans was named to the Institutional Investor’s All-America Research Team for much of his tenure, ranking first for major pharmaceuticals in 2006. His work has been highlighted in various major media outlets, including The Wall Street Journal, Barron's, The New York Times, Fortune, CNN, CBS, and Frontline.

Previously, he was a member of senior management at Roche, serving most recently as vice president, Business Policy and Account Management. In this capacity, he was responsible for Roche's commercial interactions with large organized buyers such as hospitals, hospital purchasing groups, managed-care organizations and governments. His responsibilities also included those areas of the company which define and support account interactions, namely account management, customer marketing, pricing, contract administration, pharmacoeconomics, and distribution.

During his seven years at Roche, Dr. Evans also served as the head of Business Development and Strategic Planning, and as product director for the company's injectable anesthetics. He earned a doctorate in Veterinary Medicine from North Carolina State University in 1988 and a master's of Public and Private Management from Yale University in 1991.

 

 

Mary Tanner
Founder
Life Sciences Partners

Mary C. Tanner has devoted 22 years to the health care and consumer products industry, as a Senior Managing Director at Lehman Brothers and Bear Stearns, both global investment banks. Tanner retired from Bear Stearns in 2004 and has founded Life Sciences Partners, which specializes in healthcare investment and strategic advisory work.

During her 22 years at Lehman and Bear Stearns, Ms. Tanner lead or supervised over 575 transactions, including 220 mergers, acquisitions and divestitures with a total disclosed value of $275+ billion. Among these were 14 large pharmaceutical mergers, including transactions between Rhone-Poulenc and Rorer, Rhone-Poulenc and Fisons, Marion Laboratories and Merrell Dow, Hoechst and Marion Merrill Dow, Sanofi and Sterling Drug, Sanofi and Synthelabo, BASF and Boots, Amgen and Immunex, Pfizer and Pharmacia, and Sanofi and Aventis.

Ms. Tanner also developed a large practice in the biotechnology industry as it emerged over the last 20 years, including the transactions between Roche and Genentech, Cetus and Chiron, Chiron and Behring Vaccines and others. Ms. Tanner’s expertise includes the ethical pharmaceutical industry, biotechnology, consumer self–medication, cosmetics and consumer medicine industries. In addition to her well known work with large companies, Ms. Tanner specializes in transactions between large and small companies, including corporate partnering and minority investments.

Ms. Tanner is a member of the Board of Evotec AG (Frankfurt listed), Synvista Therapeutics (AMEX listed) , and Acute Pain Therapy, Ltd (Canada) and a member of the Dean’s Council of the Yale School of Medicine. A long-time resident of New York City, Ms. Tanner is married to Frederick Frank, a Vice Chairman of Lehman Brothers and has a 15-year-old son.

Back to top

What does registration get me?

  • One (1) phone line, for you alone, or around which to gather your team(s). Toll-free in the U.S. only.
  • One (1) password to a website on which you'll view presenters’ slides.
  • An interactive Q&A round with speakers: Submit your questions for the speakers to address.
  • The insight you've come to expect and respect from Windhover and our guest speakers.

What are the unique benefits of a webinar?

  • Convenience – and lower cost.Your entire team can listen in one room. No travel required!
  • A team approach. You've often wanted to have everyone on your team getting the same knowledge and insight you derive from physical conferences. Now you can.
  • Interactivity.You're remote, but not removed. Our webinars let you ask the important, burning, controversial questions of our speakers that you'd be able to pose at a physical conference.

Back to top

And get the answers you need to achieve —
and sustain — growth in today’s dynamic market.

    About the Pharma Strategies Webinar Series

Former Intel CEO Andrew Grove coined the term “strategic inflection point” to describe the time when a business is about to experience an irrevocable change.

After 30 years of remarkable success and consistent growth, the pharmaceutical sector is at this “inflection point,” and has entered a period of uncertainty and diminished expectations. Growth has slowed in major markets, regulatory and pricing structures are more constrained, and the industry is challenged by increasing generics and a drought in R&D productivity. The once-clear template for success is now out of date, and industry leaders are looking for new organizing principles and a new framework for strategic thinking.

Join IMS and other industry experts in a webinar series hosted by Roger Longman of Windhover Information as we explore new growth opportunities in the pharmaceutical industry – where to play and how to win in an increasingly competitive, but still highly attractive market

Back to top